4.5 Article

The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers

Related references

Note: Only part of the references are listed.
Letter Infectious Diseases

Frequency of CCR5 genotypes in HIV-infected patients in Roraima, Brazil

Andre de Lima Guerra Corado et al.

BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2016)

Article Microbiology

Mechanism of active renal tubular efflux of tenofovir

Adrian S. Ray et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)

Article Biochemistry & Molecular Biology

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1

G Fätkenheuer et al.

NATURE MEDICINE (2005)

Review Pharmacology & Pharmacy

Tenofovir disoproxil fumarate - Clinical pharmacology and pharmacokinetics

BP Kearney et al.

CLINICAL PHARMACOKINETICS (2004)

Article Medicine, General & Internal

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection a randomized trial

K Squires et al.

ANNALS OF INTERNAL MEDICINE (2003)

Article Pharmacology & Pharmacy

Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively

X Wen et al.

DRUG METABOLISM AND DISPOSITION (2002)